Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects.

ABSTRACT: Primary objectives: To compare the safety among the treatment regimens, while offering continued access to blinded investigational product to subjects who have completed a prior GSK alvimopan OBD study in cancer pain subjects. Primary endpoints: Incidence of reported adverse events, including serious adverse events.

DISEASE(S): Opioid-induced Bowel Dysfunction,0 Constipation,Constipation

PROVIDER: 2515918 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Project description:Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.

| 2023988 | ecrin-mdr-crc

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain

Project description:Primary objectives: To compare alvimopan with placebo for efficacy in the treatment of OBD Primary endpoints: Proportion of subjects responding on spontaneous BM frequency

| 2517462 | ecrin-mdr-crc

Project description:Primary objectives: To compare alvimopan with placebo for efficacy in the treatment of OBD Primary endpoints: Proportion of subjects responding on spontaneous BM frequency

| 2517463 | ecrin-mdr-crc

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain

Project description:Primary objectives: To compare alvimopan with placebo for long-term safety and tolerability Primary endpoints: Incidence of reported clinical adverse events, including serious and non-serious adverse events as well as treatment-limiting adverse events

| 2517464 | ecrin-mdr-crc

Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

Project description:Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants with cancer pain. Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access to blinded investigational product to participants who have completed the original study. The purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to placebo in subjects who completed Study SB-767905/008 and elected to participate in this extension study.

| 2014660 | ecrin-mdr-crc

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects.

Project description:Primary objectives: To identify at least one alvimopan treatment regimen that improves spontaneous complete bowel movement (SCBM) frequency compared to placebo while maintaining an acceptable tolerability profile. Primary endpoints: Changes in weekly spontaneous complete bowel movement (SCBM) frequency during the 3-week Treatment Period.

| 2517533 | ecrin-mdr-crc

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Project description:Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.

| 2023761 | ecrin-mdr-crc

Project description:Primary objectives: To identify at least one orally-dosed alvimopan treatment regimen that improves spontaneous bowel movement (SBM) frequency compared to placebo while maintaining an acceptable tolerability profile. Primary endpoints: The primary endpoint is the changes in weekly spontaneous bowel movement frequency during the first 3 weeks of the 6-week Treatment Period

| 2515727 | ecrin-mdr-crc

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Project description:Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo. The primary objective of this Phase 3 long-term safety study is to compare alvimopan with placebo for safety and tolerability in the treatment of OBD. Participants will be required to attend 8 clinic visits over approximately 1 year.

| 2022618 | ecrin-mdr-crc

Baseline expression of symptomatic and asymptomatic subjects after YF17D vaccination in Trial 2

Project description:This study investigates how the baseline expression level of genes impact symptomatic outcome of flaviviral infection. Before given the YF17D vaccine, whole blood was extracted into tempus tubes from vaccinated subjects. Thereafter, the subjects were assessed if they experienced adverse events (or symptoms). 35 subjects (n=12 symptomatic, n=23 asymptomatic) were processed according to manufacturer's protocol. Transcript expression was then evaluated by nCounter RNA Cancer Metabolism (#VRXC-CM1-12) or a custom Unfolded Protein Response codeset and its respective probesets.

2019-05-11 | E-MTAB-7931 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data